Circulating androgen receptor and serum chromogranin A in castration-resistant prostate cancers (CRPC) patients treated with abiraterone and enzalutamide.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.6_suppl.160
Abstract: 160Background: Circulating aberrations (copy number/point mutation] of androgen receptor (AR) as well as serum chromogranin A (CgA) have been associated to treatment response and clinical outcome in CRPC patients (pts) treated with abiraterone (abi)/enzalutamide(enza). Methods:… read more here.
Keywords: treated abiraterone; androgen receptor; crpc patients; serum chromogranin ... See more keywords